#hepatocellular carcinoma

Checkpoint Immunotherapy Looks Promising for Operable Liver Cancer

From 1995 to 2016, hepatocellular carcinoma incidence in rural populations climbed by 218%.

Cirrhosis severity and CD4 cell counts were linked to a greater chance of developing liver cancer.

Use of cholesterol-lowering medications was also associated with reduced mortality from liver cancer and other causes.

An advisory panel reviewed follow-up data on checkpoint inhibitors, voting to maintain four approvals and rescind two.

In a small study, 80% of participants treated with Cabometyx and Opdivo underwent successful surgery.

People treated with direct-acting antivirals had better overall survival than those whose hepatitis C remained untreated.

But a simple improvement in dietary intake reversed fatty liver disease and staved off cancer.

Sintilimab plus chemotherapy infused into a liver artery may offer the chance for a cure.

Suppression of hepatitis B virus with antiviral treatment lowered the risk of hepatocellular carcinoma by 58%.

People with NAFLD have an elevated risk of cancer, largely due to high liver cancer incidence.

Weight-loss surgery especially reduced obesity-related cancers in people with liver cirrhosis.

People living with both viruses remain at risk for hepatocellular carcinoma despite antiviral therapy.

Blue Faery’s “Love Your Liver” 28-day video campaign raises awareness of liver cancer and overall liver health.